Gas Chromatography–Chemical Ionization–Mass Spectrometric Fatty Acid Analysis of a Commercial Supercritical Carbon Dioxide Lipid Extract from New Zealand Green-lipped Mussel (Perna canaliculus)
Supercritical fluid extracts of New Zealand
green-lipped mussels (NZGLM) have been suggested to have
therapeutic properties related to their oil components. The large
number of minor FA in NZGLM extract was characterized by a
GC–CIMS/MS method that excels at identification of doublebond
positions in FAME. The extract contained five major lipid
classes: sterol esters, TAG, FFA, sterols, and polar lipids. The
total FA content of the lipid extract was 0.664 g/mL. Fifty-three
unsaturated FA (UFA) were fully identified, of which 26 were
PUFA, and a further 21 UFA were detected for which concentrations
were too low for assignment of double-bond positions.
There were 17 saturated FA, with 14:0, 16:0, and 18:0 present
in the greatest concentration. The ten n-3 PUFA detected included
20:5n-3 and 22:6n-3, the two main n-3 FA; n-3 PUFA at
low concentration were 18:3, 18:4, 20:3, 20:4, 21:5, 22:5,
24:6, and 28:8. There were 43 UFA from the n-4, n-5, n-6, n-7,
n-9, and n-10 families, with 16:2n-4, 16:1n-5, 18:1n-5, 18:2n-
6, 20:4n-6, 16:1n-7, 20:1n-7, 16:1n-9, 18:1n-9, and 20:1n-9
being the most abundant. In general, we estimated that FAME
concentrations greater than 0.05% (w/w) were sufficient to assign
double-bond position. In total, 91 FA were detected in an
extract of the NZGLM, whereas previous studies of fresh flesh
from the NZGLM had reported identification of 42 FA. These
data demonstrate a remarkable diversity of NZGLM FA.
Paper no. L9596 in Lipids 40, xxx–xxx (April 2005).
The effects of Lyprinol® on delayed onset musclesoreness and muscle damage in well trainedathletes: A double-blind randomised controlled trial
The aim of the study was to determine if Lyprinol® is effective in reducing pain,
indicators of inflammation and muscle damage, and in turn improving performance in well
trained athletes suffering from delayed onset muscle soreness (DOMS).
Design: A double blind randomised placebo controlled trial.